Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)

INTRODUCTION: Currently, no treatment that delays with the progression of Friedreich ataxia is available. In the majority of patients Friedreich ataxia is caused by homozygous pathological expansion of GAA repeats in the first intron of the FXN gene. Nicotinamide acts as a histone deacetylase inhibi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neurol Res Pract
Autores principales: Reetz, Kathrin, Hilgers, Ralf-Dieter, Isfort, Susanne, Dohmen, Marc, Didszun, Claire, Fedosov, Kathrin, Kistermann, Jennifer, Mariotti, Caterina, Durr, Alexandra, Boesch, Sylvia, Klopstock, Thomas, Rodríguez de Rivera Garrido, Francisco Javier, Schöls, Ludger, Klockgether, Thomas, Pandolfo, Massimo, Korinthenberg, Rudolf, Lavin, Philip, Molenberghs, Geert, Libri, Vincenzo, Giunti, Paola, Festenstein, Richard, Schulz, Jörg B.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Clinical Trial Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650055/
https://ncbi.nlm.nih.gov/pubmed/33324899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s42466-019-0038-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares